FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1804080072> ?p ?o ?g. }

• W1804080072 endingPage "1187" @default.
• W1804080072 startingPage "1179" @default.
• W1804080072 abstract "In a positron-emission tomography (PET) study with the β-amyloid (Aβ) tracer [(18)F]-florbetaben, we previously showed that Aβ deposition in transgenic mice expressing Swedish mutant APP (APP-Swe) mice can be tracked in vivo. γ-Secretase modulators (GSMs) are promising therapeutic agents by reducing generation of the aggregation prone Aβ42 species without blocking general γ-secretase activity. We now aimed to investigate the effects of a novel GSM [8-(4-Fluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-[1-(3-methyl-[1,2,4]thiadiazol-5-yl)-piperidin-4-yl]-amine (RO5506284) displaying high potency in vitro and in vivo on amyloid plaque burden and used longitudinal Aβ-microPET to trace individual animals. Female transgenic (TG) APP-Swe mice aged 12 months (m) were assigned to vehicle (TG-VEH, n=12) and treatment groups (TG-GSM, n=12), which received daily RO5506284 (30 mg kg(-1)) treatment for 6 months. A total of 131 Aβ-PET recordings were acquired at baseline (12 months), follow-up 1 (16 months) and follow-up 2 (18 months, termination scan), whereupon histological and biochemical analyses of Aβ were performed. We analyzed the PET data as VOI-based cortical standard-uptake-value ratios (SUVR), using cerebellum as reference region. Individual plaque load assessed by PET remained nearly constant in the TG-GSM group during 6 months of RO5506284 treatment, whereas it increased progressively in the TG-VEH group. Baseline SUVR in TG-GSM mice correlated with Δ%-SUVR, indicating individual response prediction. Insoluble Aβ42 was reduced by 56% in the TG-GSM versus the TG-VEH group relative to the individual baseline plaque load estimates. Furthermore, plaque size histograms showed differing distribution between groups of TG mice, with fewer small plaques in TG-GSM animals. Taken together, in the first Aβ-PET study monitoring prolonged treatment with a potent GSM in an AD mouse model, we found clear attenuation of de novo amyloidogenesis. Moreover, longitudinal PET allows non-invasive assessment of individual plaque-load kinetics, thereby accommodating inter-animal variations." @default.
• W1804080072 created "2016-06-24" @default.
• W1804080072 creator A5002011572 @default.
• W1804080072 creator A5017253735 @default.
• W1804080072 creator A5020300464 @default.
• W1804080072 creator A5022068141 @default.
• W1804080072 creator A5026224597 @default.
• W1804080072 creator A5037412930 @default.
• W1804080072 creator A5044995419 @default.
• W1804080072 creator A5047813770 @default.
• W1804080072 creator A5065084452 @default.
• W1804080072 creator A5065710231 @default.
• W1804080072 creator A5069184646 @default.
• W1804080072 creator A5072591306 @default.
• W1804080072 creator A5074411763 @default.
• W1804080072 creator A5075261516 @default.
• W1804080072 creator A5090503237 @default.
• W1804080072 date "2015-06-09" @default.
• W1804080072 modified "2023-10-14" @default.
• W1804080072 title "Amyloid-PET predicts inhibition of de novo plaque formation upon chronic γ-secretase modulator treatment" @default.
• W1804080072 cites W1505108991 @default.
• W1804080072 cites W1891797303 @default.
• W1804080072 cites W1934667138 @default.
• W1804080072 cites W1939944131 @default.
• W1804080072 cites W1964927015 @default.
• W1804080072 cites W1965013631 @default.
• W1804080072 cites W1968588215 @default.
• W1804080072 cites W1973185157 @default.
• W1804080072 cites W1979744659 @default.
• W1804080072 cites W1980825524 @default.
• W1804080072 cites W1982816514 @default.
• W1804080072 cites W1986512401 @default.
• W1804080072 cites W1990612393 @default.
• W1804080072 cites W2011347889 @default.
• W1804080072 cites W2034102528 @default.
• W1804080072 cites W2047706826 @default.
• W1804080072 cites W2050386832 @default.
• W1804080072 cites W2052742260 @default.
• W1804080072 cites W2071695275 @default.
• W1804080072 cites W2075713420 @default.
• W1804080072 cites W2079749054 @default.
• W1804080072 cites W2081267090 @default.
• W1804080072 cites W2091241078 @default.
• W1804080072 cites W2092356280 @default.
• W1804080072 cites W2092689214 @default.
• W1804080072 cites W2097705657 @default.
• W1804080072 cites W2099331248 @default.
• W1804080072 cites W2108537069 @default.
• W1804080072 cites W2112193355 @default.
• W1804080072 cites W2113690827 @default.
• W1804080072 cites W2118935254 @default.
• W1804080072 cites W2127370803 @default.
• W1804080072 cites W2148911143 @default.
• W1804080072 cites W2153156005 @default.
• W1804080072 cites W2158854213 @default.
• W1804080072 cites W2171883423 @default.
• W1804080072 cites W2178572083 @default.
• W1804080072 cites W2191112769 @default.
• W1804080072 cites W274427711 @default.
• W1804080072 cites W79754231 @default.
• W1804080072 cites W84124737 @default.
• W1804080072 doi "https://doi.org/10.1038/mp.2015.74" @default.
• W1804080072 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4759098" @default.
• W1804080072 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26055427" @default.
• W1804080072 hasPublicationYear "2015" @default.
• W1804080072 type Work @default.
• W1804080072 sameAs 1804080072 @default.
• W1804080072 citedByCount "42" @default.
• W1804080072 countsByYear W18040800722015 @default.
• W1804080072 countsByYear W18040800722016 @default.
• W1804080072 countsByYear W18040800722017 @default.
• W1804080072 countsByYear W18040800722018 @default.
• W1804080072 countsByYear W18040800722019 @default.
• W1804080072 countsByYear W18040800722020 @default.
• W1804080072 countsByYear W18040800722021 @default.
• W1804080072 countsByYear W18040800722022 @default.
• W1804080072 crossrefType "journal-article" @default.
• W1804080072 hasAuthorship W1804080072A5002011572 @default.
• W1804080072 hasAuthorship W1804080072A5017253735 @default.
• W1804080072 hasAuthorship W1804080072A5020300464 @default.
• W1804080072 hasAuthorship W1804080072A5022068141 @default.
• W1804080072 hasAuthorship W1804080072A5026224597 @default.
• W1804080072 hasAuthorship W1804080072A5037412930 @default.
• W1804080072 hasAuthorship W1804080072A5044995419 @default.
• W1804080072 hasAuthorship W1804080072A5047813770 @default.
• W1804080072 hasAuthorship W1804080072A5065084452 @default.
• W1804080072 hasAuthorship W1804080072A5065710231 @default.
• W1804080072 hasAuthorship W1804080072A5069184646 @default.
• W1804080072 hasAuthorship W1804080072A5072591306 @default.
• W1804080072 hasAuthorship W1804080072A5074411763 @default.
• W1804080072 hasAuthorship W1804080072A5075261516 @default.
• W1804080072 hasAuthorship W1804080072A5090503237 @default.
• W1804080072 hasBestOaLocation W18040800721 @default.
• W1804080072 hasConcept C102230213 @default.
• W1804080072 hasConcept C104317684 @default.
• W1804080072 hasConcept C126322002 @default.
• W1804080072 hasConcept C134018914 @default.
• W1804080072 hasConcept C141035611 @default.

• next